Skip to main content
OpenTrials
Completed

NCT Number: NCT04007081

Salivary Gland Autotransplantation for Treatment of XRT Induced Xerostomia

Xerostomia, or dry mouth, is a common side effect of head neck radiation. Current treatment options for radiation-induced xerostomia are generally supportive in nature. Most of these supportive interventions do not reverse xerostomia and are palliative in intent.

The investigators propose that autotransplantation of marrow-derived mesenchymal stromal cells (MSCs) in salivary glands post-RT or post-chemoradiation therapy (CRT) may provide an innovative remedy to treat xerostomia and restore quality of life.

Participants can expect to be on study for up to 6 months.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–89 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Wisconsin Carbone Cancer Center

Madison, Wisconsin, 53705, United States

About this study

This feasibility study will analyze the salivary composition, salivary viscoelasticity, salivary gland US, and QoL surveys of participants without head and neck cancer (HNC) to determine standard values. The investigators will then compare this to the salivary composition and viscoelasticity of participants with treated HNC.

Additionally, the investigators will examine the paracrine factors of marrow MSCs in order to prove a hypothesis that paracine factors constitutively expressed by marrow MSCs [Wnts, fibroblast growth factors (FGFs), GDNF and others] will directly influence the biology of dormant salivary gland stem cells following intraglandular transplantation and allow for functional recovery following RT.

Primary Objective

  • To determine the feasibility of in vitro expansion of marrow-derived MSCs from HNC patients to >50 million cells.

Secondary Objectives

  • To assess the stability of salivary function in HNC patients using quality-of-life (QoL) questionnaires and salivary composition analysis.
  • To assess the stability of salivary gland size as measured by ultrasound.

Correlative Objectives

  • To compare assess the secretome profile of MSCs from HNC patients treated with radiation or, chemoradiation, or previously untreated.
  • To compare the salivary composition, viscoelasticity, salivary gland ultrasound, and QoL of HNC patients to non-HNC patients

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants ≥2 years from completion of chemoradiation therapy or radiation therapy (N=6) with subjective complaint of xerostomia or with no diagnosis of HNC (N=5)
  • Karnofsky ≥ 60, participant eligible for bone marrow aspirate with wakeful anesthesia
  • Not pregnant
  • Willing and able to give informed consent
  • non-HNC participants only need to meet the following applicable inclusion criteria
  • No history of radiation to the salivary glands
  • Willing and able to give informed consent

Exclusion criteria

  • Salivary gland disease (e.g., sialolithiasis)

Treatment and study plan

Bone Marrow Aspiration

Procedure

collection of approximately 40 mL of bone marrow aspirate

Other names: Bone Marrow Collection

Ultrasound Imaging of Salivary Glands

Diagnostic Test

Salivary gland size will be measured by ultrasound.

Salivary Assay

Other

Whole saliva production rates (sialometry) will be measured under unstimulated (first passive drool method) and stimulated (chewing gum) saliva collection conditions

Other names: sialometry

Quality of Life Instruments

Other

Participants will self-assess with the following Quality of Life (QoL) surveys: University of Michigan Xerostomia related quality of life scale (XeQOL), the MD Anderson Dysphagia Index (MDADI), and the VAS xerostomia questionnaire.

Primary outcomes

  1. Number of Participant's whose Marrow-Derived MSCs Can be Expanded in vitro to > 50 million cells within two weeks

    Time frame: Up to 1 day to collect, subsequently cultured in vitro for up to 2 weeks

    The feasibility of in vitro expansion of MSCs derived from marrow aspirates collected from participants will be determined by if they can be culture expanded for up to two weeks to generate >50 million MSCs per donor. Feasibility will reported as the number of participants whose marrow-derived MSCs can be expanded in vitro to > 50 million cells within two weeks.

Secondary outcomes

  1. Change in participant QoL: XeQOL

    Time frame: baseline and up to 6 months

    The University of Michigan Xerostomia related quality of life scale (XeQOL) is a 15-item questionnaire about how a participants oral health affects their life. Each item is scored from 1-5 either 'not at all', 'a little', 'somewhat', 'quite a bit', or 'very much' for a total score of 15-75. Higher scores represent greater degree of symptoms.

  2. Change in participant QoL: MDADI

    Time frame: baseline and up to 6 months

    The MD Anderson Dysphagia Inventory (MDADI) is a 20-item questionnaire about how a participants perceive their swallowing ability. Each item is scored from 'strongly agree', 'agree', 'no opinion', 'disagree', or 'strongly disagree'. One question provides a 'global score between 1-5 where 1 is extremely low functioning and 5 is high functioning. The remaining 19 questions measure a composite score from 20-100 where higher scores represent higher degree of function.

  3. Change in participant QoL: VAS

    Time frame: baseline and up to 6 months

    The Visual Analogue Scale (VAS) - xerostomia questionnaire is an 8-item questionnaire about how a participant perceives their dry mouth. Each item is visually scored on a sliding scale (100mm in length) between two extremes (Q1 and Q2 from 'not difficult at all' to 'very difficult', Q3 from 'A lot' to 'None', Q4-Q7 from 'Not Dry at All' to 'Very Dry', and Q8 from 'Not Thirsty at All' to 'Very Thirsty'. The participant places a line on the scale to mark their answer. Change between various time points can be determined based on measured distance along the scale for each answer.

  4. Change in participant Salivary Function: Unstimulated

    Time frame: baseline and up to 6 months

    Unstimulated saliva production will be measured at two time points by the passive drool method over a 5-minute time frame. Participants will allow saliva to pool in the mouth and, then, with head tilted forward, gently guide saliva into a saliva collection aid attached to a cryovial. Difference in weight of the cryovial empty and after the test will represent the amount of saliva produced.

  5. Change in participant Salivary Function: Stimulated

    Time frame: baseline and up to 6 months

    Stimulated saliva production will be measured at two time points by having participants chew inert gum base to the pace of a metronome (70 beats per minute) while expectorating saliva (without swallowing) into the saliva collection aid for 5 minutes total. Difference in weight of the cryovial empty and after the test will represent the amount of saliva produced.

  6. Change in participant Salivary Gland Size

    Time frame: baseline and up to 6 months

    The size of salivary glands will be measured via ultrasound at baseline and up to 6 months on study.

Other outcomes

  1. Compare Secretome Profile of MSCs Between Participant Groups: ELISA

    Time frame: up to 6 months

    The secretome profile of MSCs from HNC participants treated with radiation, chemoradiation, or previously untreated will be statistically compared using enzyme-linked immunosorbent assay (ELISA).

  2. Compare Secretome Profile of MSCs Between Participant Groups: Western Blot

    Time frame: up to 6 months

    The secretome profile of MSCs from HNC participants treated with radiation, chemoradiation, or previously untreated will be statistically compared using and western blots.

Sponsors and collaborators

Lead sponsor

University of Wisconsin, Madison

Other

Registry information

Official study title

Salivary Gland Autotransplantation of Marrow Mesenchymal Stromal Cells for Treatment of Radiation-induced Xerostomia - FDA IND (Investigational New Drug) Enabling Studies

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Jul 5, 2019
Registry last updated
Mar 24, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.